Skip to main content

First PROTAC Degradation of Mulit-Pass Transmembrane Protein

Cancer cells exploit proteins involved in energy metabolism to maintain a steady supply of building blocks necessary for increased proliferation. Many transporters play a role in the process of shuttling water, nutrients, ions, and various metabolic products across the cell membrane, including the solute carrier (SLC) group of proteins. The SLC protein group consists of more than 400 proteins organized into more than 50 families. For example, the SLC9 family is involved in intracellular pH homeostasis, with increased SL9 activity resulting in an elevated intracellular pH and cytosolic alkalinization in cancer. Currently there 12 FDA approved drugs targeting SLC proteins for conditions ranging from hypertension to depression, but recent studies suggest SLC proteins may be attractive targets for cancer drug development.


With this end goal, Bensimon et al., aimed to investigate if multi-pass transmembrane proteins like SLCs can be chemically degraded. To first explore this aim, they used the dTAG system to determine that SLCs can undergo phthalimide-mediated degradation using a sample of 13 SLCs. Given that SLCs can localize to differing subcellular locals, they observed various degrees of degradation, but overall all the SLCs tested except those localized to the inner mitochondrial membrane were able to undergo proteasome-mediated degradation. This process was confirmed to require proteolytic machinery using competition experiments including co-treatment of cullin neddylation using a NAE1 inhibitor, addition of excess pomalidomide to saturate CRBN binding, and treatment with proteasome inhibitors. 

Due to limitations with using the dTag approach to genetically degrade SLCs, the group designed a library of SLC9A1 PROTACs based on a previously published SLC9A1 inhibitor to determine if SLC group members can be chemically degraded. SLC9A1 (aka NHE1) exchanges one Na+ ion for one H+ ion contributing to a more alkaline intracellular environment as mentioned above. One of the PROTACs, d9A-2 was able to degrade endogenous SLC9A1 with sub-micromolar concentration in two chronic myelogenous leukemia (CML) cell lines.


The authors also investigated the effect of d9A-2 treatment on SLC9 functionality and cell viability. SLC9 function can be tested by examining the ability of cells to recover from acid load. Compared to the warhead, d9A-2 showed a significant defect in acid recovery with 1 M of PROTAC having the same effect as 25 uM of warhead. The novel SLC PROTAC also showed varied cytotoxicity across cell lines, having the greatest effect on leukemic cancers with an EC50 less than 0.1 uM.  


In conclusion, the Superti-Furga group developed the first SLC PROTAC. This is also the first multi-pass trans-membrane PROTAC, suggesting that in the future even GPCRs can be proteolytically degraded.

Comments

Post a Comment

Popular posts from this blog

Photoswitchable azopyrazoles Flipping the Switches of Ion Channels

Abnormally activated Ca 2+ channels are related to many human diseases, including Stormorken Syndrome, which makes Ca 2+ release-activated Ca 2+ (CRAC) channel a very promising therapeutic target. Several small molecule therapeutics targeting CRAC channels have been developed, including the GSKs series and Synta 66 . Those compounds have relatively high specificity. Meanwhile, a controllable system that can be activated with a switch can probably serve as a convenient tool for further related research.    Photoswitchable chemistry has been applied to a lot of bioactive targets such as ion channels, receptors enzymes and nucleic acids. Recently, the Li group developed CRAC channel inhibitors that can be turned ‘on’ and ‘off’ by UV-light exposure. Scheme 1 . C onverting CRAC channel inhibitors, GSKs , into photoswitchable derivatives, piCRACs . Starting from the well-established GSK-based CRAC inhibitor ( Scheme 1 ), the authors developed a series of nitrosaniline
1 comment
Read more

Proteosome Inhibition Taps Into RNA Splicing

Multiple myeloma (MM) is a malignancy of white blood cells called plasma cells that reside mainly in the bone marrow and is the second most common blood cancer. With increased understanding of biology, the current use of immunomodulatory (IM) drugs and proteasome inhibitors (PI) have taken over the therapeutic landscape for MM. The combination of bortezomib (PI) with lenalidomiede (IM) and dexamethasone is commonly the initial treatment of choice. Early intervention seems to provide a good outcome, but unfortunately, many patients eventually relapse. A major goal in MM treatment is to increase the efficacy of proteasome inhibitors and prevent relapse. To investigate this, Huang et al. used unbiased mass spectrometry-based phosphoproteomics to identify potential vulnerabilities after treatment with the PI carfilzomib and discovered that splicing related proteins had significant changes in phosphorylation that is undetectable upon examination of RNA and protein abundance. Treatment w
Post a Comment
Read more

One Fluorine Atom Fixes Poor KRAS Inhibitors

KRAS  is the most frequently mutated oncogene in human cancer. In the past few decades, the KRAS oncoprotein had always been deemed as an “undruggable target” due to lack of binding surface and tightly binding to its substrate GTP. In 2013, the Shokat group identified that the mutant cysteine KRAS G12C creates a new allosteric pocket “switch-II pocket” which can be exploited to design covalent inhibitors. KRAS G12C accounts for more than 50% of the incidences of KRAS mutations, involving in many cancers, such as non-small cell lung cancer (NSCLC), colorectal adenocarcinomas and pancreatic cancer. KARS G12C has been an attractive target for drug discovery and development in both academia and industry. MRTX849 is a potent, orally available covalent inhibitor of KRAS G12C developed by Mirati Therapeutics and currently undergoing Phase I/II clinical trials. Recently, a paper published in Journal of Medicinal Chemistry reported the design and optimization of MRTX849 . The medi
Post a Comment
Read more